Literature DB >> 28554545

Cyclodextrin-mesoporous silica particle composites for controlled antibiotic release. A proof of concept toward colon targeting.

Louise Stjern1, Sandra Voittonen1, Rahel Weldemichel1, Sofia Thuresson1, Marco Agnes2, Gabor Benkovics3, Éva Fenyvesi3, Milo Malanga3, Konstantina Yannakopoulou2, Adam Feiler4, Sabrina Valetti5.   

Abstract

Cyclodextrins (CDs) and mesoporous silica particles (MSPs) have been combined as composite carriers for controlled antibiotic release. CDs were employed as "gatekeeper" agents and grafted onto MSPs to retain drug molecules inside the MSP carrier. A variety of CDs (unfunctionalized, positively charged and carboxymethylated) and three different coupling strategies (covalent binding, electrostatic adsorption and inclusion complexation) were systematically investigated for their ability to control the release of two antibiotic drugs, metronidazole and clofazimine. The drugs had significantly different physicochemical properties (metronidazole - small hydrophilic, clofazimine- large hydrophobic). We report for the first time on the encapsulation and characterization of metronidazole-loaded-MSP. Each CD coating strategy reduced the drug release rate in phosphate buffer compared to unmodified MSP (from 20% to 100% retained drug). Covalent binding and inclusion complex approaches were significantly more effective than electrostatically adsorbed CD. In particular, the novel inclusion complex based on host/guest interaction between benzyl-modified silica surface and α-CD proved to be very effective (60-100% retained drug amount). Using pharmaceutical manufacturing processes, our study shows that CD-MSP composites can retain both hydrophobic and hydrophilic antibiotic compounds with potential translation to triggered release formulation targeting bacterial infections in the colon and lower intestine.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clofazimine; Clofazimine (PubChem CID: 2794); Colon targeting; Controlled drug release; Cyclodextrin; Gatekeeper; Mesoporous silica particle; Metronidazole; Metronidazole (PubChem CID: 4173); α-cyclodextrin (PubChem CID: 444913)

Mesh:

Substances:

Year:  2017        PMID: 28554545     DOI: 10.1016/j.ijpharm.2017.05.062

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

1.  Development and Characterization of Celecoxib Solid Self-nanoemulsifying Drug Delivery Systems (S-SNEDDS) Prepared Using Novel Cellulose-Based Microparticles as Adsorptive Carriers.

Authors:  Fabian-Pascal Schmied; Alexander Bernhardt; Victor Baudron; Birte Beine; Sandra Klein
Journal:  AAPS PharmSciTech       Date:  2022-08-03       Impact factor: 4.026

2.  Improving the Solubility, Dissolution, and Bioavailability of Metronidazole via Cocrystallization with Ethyl Gallate.

Authors:  Jinhui Li; Xinghui Hao; Chenguang Wang; Haiyan Liu; Lianchao Liu; Xin He; Changquan Calvin Sun
Journal:  Pharmaceutics       Date:  2021-04-14       Impact factor: 6.321

3.  Encapsulation of Metronidazole in Biocompatible Macrocycles and Structural Characterization of Its Nano Spray-Dried Nanostructured Composite.

Authors:  Mirella Mirankó; Mónika Megyesi; Zsombor Miskolczy; Judit Tóth; Tivadar Feczkó; László Biczók
Journal:  Molecules       Date:  2021-12-02       Impact factor: 4.411

Review 4.  Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability.

Authors:  Daniel Andrés Real; Karen Bolaños; Josefina Priotti; Nicolás Yutronic; Marcelo J Kogan; Rodrigo Sierpe; Orlando Donoso-González
Journal:  Pharmaceutics       Date:  2021-12-10       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.